Latest Cancer News

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients (10-24-2016)

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical resection. In the study, Yervoy compared with placebo significantly improved overall survival (OS) with [...]

Tesaro Provides Real Benefit to Ovarian Cancer Patients (10-20-2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro improved cancer-free survival by 73% in patients with a BRCA mutation and by 55% in those without such mutations. The new [...]

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer (10-19-2016)

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with [...]

The HPV Vaccine Prevents Lesions That Could Cause Cervical Cancer by 50 Percent (10-13-2016)

A recent report published online Sept. 29 in the journal JAMA Oncology suggests that the vaccine against human papillomavirus (HPV) infection, which doctors believe causes most cases of cervical cancer, is more effective than previously thought. Human papillomaviruses consist of more than 100 different viruses. Some types of HPV cause [...]

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma (10-12-2016)

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this trial clearly demonstrated that ASCT should remain the preferred treatment for younger patients [...]

Epacadostat Plus Keytruda® Appears Effective in Melanoma (10-11-2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery, melanoma has a high cure rate. However, once melanoma invades deeper [...]

Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life (10-10-2016)

According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health of patients even a year before their diagnosis. Myeloproliferative neoplasms (MPN) are a related group of blood cancers. In these disorders, the bone marrow cells that produce blood cells develop [...]

FDA Warns Against Ovarian Cancer Screening Tests (10-6-2016)

According to the US Food and Drug Administration (FDA) doctors and their patients should not use certain ovarian cancer screening tests because of inaccurate results. Screening tests are designed to detect cancer in its earliest stages when it is most treatable. Inaccurate tests however, can miss a cancer diagnosis when [...]

PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment (10-5-2016)

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment for head and neck cancer is working after just one cycle of chemotherapy. The ability to identify a patients [...]

A New Drug That ‘Wakes Up’ Immune System Appears to Fight Pancreatic Cancer (10-4-2016)

A novel drug, IMM-101 has extended the lives of some people with metastatic pancreatic cancer and appears to have minimal side-effects. Doctors describe IMM-101 as “waking up” the immune system to attack cancer. Patients who were given the new immunotherapy drug actually felt better than those who were on standard [...]

Different Treatment Options Appear Equally Effective in Early Prostate Cancer (10-3-2016)

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10 years. Spread of cancer, however, was higher among those whose cancer was monitored until progression. [...]

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia (09-26-2016)

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience survival benefits with the addition of Rituxan® (rituximab) to standard chemotherapy. ALL in children is a malignant disease, or cancer of the blood, characterized by the [...]

Next Page »